Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
Rhea-AI Summary
Annovis (NYSE: ANVS) promoted Cheng Fang, Ph.D., to Chief Scientific Officer. Fang, formerly Senior VP of R&D, will lead scientific strategy and research operations for the company’s Alzheimer’s and Parkinson’s programs.
The move comes as Annovis advances its oral therapy buntanetap toward Phase 3 Alzheimer’s top-line data and a potential NDA submission.
Positive
- None.
Negative
- None.
News Market Reaction – ANVS
In the Jul 1 session, ANVS gained 3.23%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 26 | Listing compliance update | Positive | -7.6% | Regained NYSE listing compliance after cure plan raised market cap and equity. |
| May 20 | Dilutive equity offering | Negative | -0.8% | Priced $15M stock and warrant offering at $1.90 to fund Phase 3 work. |
| May 19 | Equity offering launch | Negative | -0.8% | Announced proposed stock and warrant offering to fund buntanetap development. |
| May 15 | Quarterly earnings update | Negative | -3.3% | Reported higher R&D spending, larger net loss and limited cash for late-stage trials. |
| May 07 | Conference presentation | Positive | -5.8% | CEO scheduled to present multi‑protein Alzheimer’s model and highlight buntanetap program. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows ANVS often trading lower after both positive corporate updates and dilutive financing or earnings news.
Key Terms
phase 3 clinical
translational science medical
biomarker medical
new drug application (nda) regulatory
neurodegenerative diseases medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the promotion of Cheng Fang, Ph.D., to Chief Scientific Officer.
Dr. Fang, who joined Annovis in 2021 and most recently served as Senior Vice President, Research and Development, will lead scientific strategy and research operations across the Company's AD and PD programs, including translational science, clinical development, biomarker strategy, and regulatory interactions. Her promotion comes at a pivotal moment, as Annovis advances its lead drug candidate, buntanetap, toward top-line data readout from the pivotal Phase 3 AD study and a subsequent New Drug Application (NDA) submission.
"Cheng has been instrumental in deepening our understanding of buntanetap's therapeutic potential, designing and overseeing rigorous, high-quality clinical trials that integrate both traditional cognitive and functional as well as innovative biomarker endpoints," said Maria Maccecchini, Ph.D., Founder, President and Chief Executive Officer of Annovis Bio. "Her dedication and expertise have brought us to the cusp of a defining moment for our company and for the patient community. As we approach these pivotal scientific and regulatory milestones, there is no one better suited to lead our scientific efforts forward."
"I am honored to take on this role at such a defining moment for Annovis," said Cheng Fang, Ph.D., Chief Scientific Officer. "I am proud of the work our team has put into advancing buntanetap, and I am energized by what lies ahead. I look forward to building on this foundation as we work to bring a meaningful new therapy to the patients and families who are counting on us."
Dr. Fang has held multiple senior leadership and academic roles spanning translational research, clinical development, and regulatory strategy, with a sustained focus on understanding and treating neurodegenerative diseases. She earned her Ph.D. in Neuroscience from The Pennsylvania State University and her B.S. in Biopharmaceutical Sciences from Nanjing University.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com
